Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.46 SEK | +8.81% | +8.12% | +12.70% |
Apr. 10 | Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 | CI |
Feb. 22 | Newbury Pharmaceuticals Secures SEK9 Million Sales Order | MT |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.70% | 7.4M | - | - | |
-15.68% | 7.78B | B | ||
+30.84% | 1.32B | - | ||
-12.79% | 343M | - | ||
+2.79% | 275M | - | ||
+8.89% | 222M | - | - | |
-25.69% | 73.97M | - | - | |
+28.21% | 61.04M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- NEWBRY Stock
- Ratings Newbury Pharmaceuticals AB